Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Non-alcoholic Steatohepatitis Treatment Market

Non-alcoholic Steatohepatitis Treatment Market Share

Report ID: GMI10894
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Non-alcoholic Steatohepatitis Treatment Market Share

The non-alcoholic steatohepatitis (NASH) treatment market is experiencing robust growth due to continuous innovation and technological advancements. This market expansion is fuelled by leading companies in the healthcare sector that are striving to provide a diverse range of advanced treatments, including both medications and innovative therapies. These companies are consistently investing in research and development to introduce new products and enhance existing ones.

Non-alcoholic Steatohepatitis Treatment Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are in the clinical development phase. The prominent players considered in the market are as mentioned below:

AstraZeneca
Bristol-Myers Squibb Company
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Genfit
Gilead Sciences, Inc.
Immuron Ltd
Intercept Pharmaceuticals, Inc.
Madrigal Pharmaceuticals
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Zydus Cadila

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The non-alcoholic steatohepatitis treatment industry size was USD 5.5 billion in 2023 and is expected to showcase 29.9% CAGR from 2024 to 2032 due to increasing prevalence of metabolic disorders

The oral route of administration segment accounted for 63.6% of the market share in 2023 due to several advantages, such as ease of administration, patient compliance, and cost-effectiveness

North America non-alcoholic steatohepatitis treatment industry is expected to reach USD 23.2 billion by 2032 due to serious complications like cirrhosis and liver cancer if left untreated.

AstraZeneca, Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Inc., Immuron Ltd, and Intercept Pharmaceuticals, Inc.